Share this article
mRNA vaccine is first fully made-in-Canada vaccine to undergo trials
TORONTO and CALGARY, AB, Dec. 23, 2020 /CNW/ - Providence Therapeutics today announced that Health Canada has provided a Notice of Authorization for its Clinical Trial Application. This permits the Canadian biotech company to begin human clinical trials of its COVID-19 vaccine. PTX-COVID19-B is a messenger RNA (mRNA) vaccine and is the first fully made-in-Canada COVID vaccine to reach this stage of development.
Health Canada s authorization means Phase I clinical trials will begin early in the New Year. Later phase clinical trials are expected to proceed in 2021, subject to regulatory approval.